161 related articles for article (PubMed ID: 37840059)
61. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
[TBL] [Abstract][Full Text] [Related]
62. Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan.
Fukano R; Mori T; Kobayashi R; Mitsui T; Fujita N; Iwasaki F; Suzumiya J; Chin M; Goto H; Takahashi Y; Hara J; Park YD; Inoue M; Koga Y; Inagaki J; Sakamaki H; Adachi S; Kawa K; Kato K; Suzuki R
Br J Haematol; 2015 Feb; 168(4):557-63. PubMed ID: 25312752
[TBL] [Abstract][Full Text] [Related]
63. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
64. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
65. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
66. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.
Doocey RT; Toze CL; Connors JM; Nevill TJ; Gascoyne RD; Barnett MJ; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Shepherd JD; Sutherland HJ; Voss NJ; Smith CA; Song KW
Br J Haematol; 2005 Oct; 131(2):223-30. PubMed ID: 16197454
[TBL] [Abstract][Full Text] [Related]
68. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
Yasuda S; Najima Y; Konishi T; Yamada Y; Nagata A; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Shingai N; Yoshioka K; Inamoto K; Mukae J; Toya T; Igarashi A; Shimizu H; Kobayashi T; Kakihana K; Sakamaki H; Kawamata N; Ohashi K; Doki N
Leuk Res; 2021 Sep; 108():106627. PubMed ID: 34062327
[TBL] [Abstract][Full Text] [Related]
69. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
[TBL] [Abstract][Full Text] [Related]
70. Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
Beynarovich A; Lepik K; Mikhailova N; Borzenkova E; Volkov N; Moiseev I; Zalyalov Y; Kondakova E; Kozlov A; Stelmakh L; Pirogova O; Zubarovskaya L; Kulagin A; Afanasyev B
Int J Hematol; 2022 Sep; 116(3):401-410. PubMed ID: 35511399
[TBL] [Abstract][Full Text] [Related]
71. Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain.
Martínez C; Carpio C; Heras I; Ríos-Herranz E; Buch J; Gutierrez A; Romero S; Zeberio I; García-García I; Rodriguez-Izquierdo A; Alonso R; Bargay J; Barrenetxea C; Domingo-Doménech E; de Haro ME; Palomera L; García-Sanz R;
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1534-1542. PubMed ID: 32068094
[TBL] [Abstract][Full Text] [Related]
72. Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.
Bai L; Zhang YZ; Yan CH; Wang Y; Xu LP; Zhang XH; Zhang LP; Huang XJ; Cheng YF
BMC Cancer; 2022 Aug; 22(1):896. PubMed ID: 35974319
[TBL] [Abstract][Full Text] [Related]
73. Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study.
Zhou W; Chen G; Gong D; Gao Y; Yu L
Front Oncol; 2023; 13():1138853. PubMed ID: 36845681
[TBL] [Abstract][Full Text] [Related]
74. Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma.
Fujita N; Kobayashi R; Atsuta Y; Iwasaki F; Suzumiya J; Sasahara Y; Inoue M; Koh K; Hori T; Goto H; Ichinohe T; Hashii Y; Kato K; Suzuki R; Mitsui T
Int J Hematol; 2019 Apr; 109(4):483-490. PubMed ID: 30701466
[TBL] [Abstract][Full Text] [Related]
75. Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.
Li Z; Zhang B; Fan X; Gui R; Yu F; Wang J; Zhang Y; Zhou K; Liu Y; Li Y; Ding J; Song Y; Zhou J
Front Oncol; 2023; 13():1193237. PubMed ID: 37546390
[TBL] [Abstract][Full Text] [Related]
76. Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma.
Peng YY; Xiong YY; Zhang LX; Wang J; Zhang HB; Xiao Q; Guo SL
Turk J Haematol; 2021 Jun; 38(2):126-137. PubMed ID: 33535731
[TBL] [Abstract][Full Text] [Related]
77. [Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for T lymphoblastic leukemia/lymphoma].
Luo L; Jiao Y; Yang P; Li Y; Huang WY; Ke XY; Zou DH; Jing HM
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):388-394. PubMed ID: 37550188
[No Abstract] [Full Text] [Related]
78. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
[TBL] [Abstract][Full Text] [Related]
79. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
[TBL] [Abstract][Full Text] [Related]
80. Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Cui JK; Xiao Y; You Y; Shi W; Li Q; Luo Y; Jiang L; Zhong ZD
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):693-698. PubMed ID: 29058281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]